Abstract: Cyclic peptide of formula (1) where Xaa1 is selected from L-amino acids selected from Phe, Lys and Arg, D-amino acids selected from Phe and Met, the L- and D-amino acid optionally substituted on its &agr;-carbon or its &agr;-amino group with a C1-4 alkyl group; and Melle; Xaa2, Xaa3 et Xaa4 are respectively Leu, Asp and Val, optionally substituted on their &agr;-carbon or &agr;-amino group with a C1-4 alkyl group; X1 is selected from D-amino acids selected from Ala, Phe, Arg, Lys, Trp, hArg(Et)2, Orn(CHMe2), Orn(Me2), Lys(CHMe2) and Arg(Pmc), optionally substituted on their &agr;-carbon or &agr;-amino group with a C1-4 alkyl group; Formula (II); NH(CH2)5CO; and NH(CH2)2S(CH2)yCO, where y is 1 or 2; X2 is selected from D-amino acids selected from Ala, Arg, Lys, His, hArg(Et)2, Orm(CHMe2), and Om(Me2), optionally substituted on their &agr;-carbon or &agr;-amino group with a C1-4 alkyl group; NH(CH2)SCH2CO; and NH(CH2)xCO, where x is 2 or 3; Xaa5 and Xaa6 are each independently a

Abstract: Pharmaceutical compositions comprising an inhibitor of ras farnesylation of formula (I) wherein, R1 is for example H and further values as defined in the specification; R2 is for example H and further values as defined in the specification; R3 is for example H or a substituent having values as defined in the specification; p is 0-3 in which R3 values can be the same or different; L is a linking moiety for example —CO—NH2— and further values as defined in the specification; A is selected from phenyl; naphthyl; a 5-10 membered monocyclic or bicyclic heteroaryl ring containing up to 5 heteroatoms where the heteroatoms are independently selected from O, N and S; or a —S—S— dimer thereof when R2=H; or an enantiomer, diastereoisomer, pharmaceutically acceptable salt, prodrug or solvate thereof together with a pharmaceutically acceptable diluent or carrier. A particular use is cancer therapy.

Abstract: An ink composition comprising: (a) from 0.1 to 50 parts of a dye; (b) from 0.1 to 50 parts of a sugar; (c) from 0.1 to 50 parts of a compound selected from phosphoric acid and a carboxylic acid or a salt thereof; (d) from 0 to 10 parts of a pH buffer; and (e) from 10 to 99 parts of a liquid medium; wherein all parts are by weight and the total number of parts (a)+(b)+(c)+(d)+(e)=100. Also claimed is a recording sheet comprising a substrate coated or impregnated with a sugar, a compound selected from phosphoric acid and a carboxylic acid or a salt thereof and optionally a binder; a coating composition; a method of ink jet printing; a substrate printed according to the method; and an ink jet printer cartridge which contains the ink and/or the coating composition.

Abstract: The present invention relates to compounds, pharmaceutical compositions and methods of using compounds having the formula below in the treatment and prevention of certain diseases or conditions. Where the ring designated A is chosen from ortho substituted aryl or heteroaryl species, R1 and R2 are chosen independently from —(CH2)nL where L is selected from a variety of substituents including hydrogen, and aryl, heteroaryl or heterocyclic groups and R4 is chosen from a variety of substituents including halogen and alkyl groups. The compounds are useful in treating and preventing neurological disorders associated with excitatory amino acids.

Abstract: The present invention provides a phenanthroline derivative of formula (I) 1

Abstract: A promoter comprising the DNA sequence of an oil seed rape cysteine protease gene promoter of class 1, 2 or 6 is described. The promoter may be used in an expression system for at least the tissue or tissues of a germinating seedling or developing grain or plant (e.g. in the root, cotyledons, leaves and stem). In a preferred embodiment, the expression system comprises a disrupter gene fused to a promoter according to the present invention.

Abstract: The formation of undesirable sludge in the course of spraying a solution or dispersion of a water-soluble or water-dispersible solid or a structured gel formulation is reduced by the incorporation in the formulation of a low-density solid particulate material having a density of less than one and a diameter of less than the spray nozzle filter through which it will pass. The low-density solid particulate material is preferably a hollow glass or plastic particle having a density of less than 0.8 g/cm3. The invention is particularly applicable to agrochemical formulations.

Abstract: There is provided a process for the preparation of 1,1,1-trichlorotrifluororethane in which 1,1-dichloro-2,2,2-trifluoroethane is subjected to chlorination by bringing the 1,1-dichloro-2,2,2-trifluoroethane into contact with chlorine within a reaction vessel characterised in that the process is conducted in the liquid phasein the presence of a chemical free radical initiator under a pressure of from 1 to 20 bar and at a temperature within the range 50 to 120° C., and the product is separated from the reaction mixture by fractional distillation. The product is useful in the manufacture of insecticides.

Abstract: The invention concerns compounds of formula (I), wherein each of G1, G2 and G3 is CH or N; m is 1 or 2; R1 includes hydrogen, halogeno and 1-C)alkyl; M1 is a group of formula: NR2—L1—T1R3, in which R2 and R3 together form a (1-4C)alylene group, L1 includes (1-4C)alkylene, and T1 is CH or N; A may be a direct link; M2 is a group of the formula: (T2R4)rL2—T3R5 in which R is 0 or 1, each of T2 and T3 is CH or N, each of R4 and R5 is hydrogen or (1-4C)alkyl, or R4 and R5 together form a (1-4C)alkylene group, and L2 includes (1-4C)alkylene; M3 may be a direct link to X; X includes sulphonyl; and Q includes naphthyl and a heterocyclic moiety; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use as antithrombotic or anticoagulant agents.

Abstract: A process for the preparation of a substituted aromatic compound in which a chloroaromatic compound and an alkyl-, alkenyl- or aryl-boronic acid ester or anhydride are coupled in the presence of palladium and a lipophilic aliphatic phosphine comprising at least one branched aliphatic group or a lipophilic aliphatic Dis(phosphine). Preferred phosphines include triisopropyl, triisobutyl and tricyclohexylphosphine.

Abstract: A process for preparing a compound of Formula (I); where Q completes an optionally substituted 5-or 6-member saturated carbocyclic ring and R is optionally substituted phenyl or optionally substituted C3-C6 cycloalkyl which comprises the rearrangement of a compound of Formula (II); where Q and R are as defined in relation to Formula (I) in a polar aprotic, dipolar aprotic or aromatic hydrocarbon solvent in the presence of a moderate base and an azole.

Abstract: The invention relates to a transgenic or mutated plant having genomic material which alters the normal starch synthesis pathway within the plant. More specifically, the present invention relates to a plant having a genotype which creates new forms of starch in significant quantity. Particularly, the invention relates to grain having an embryo with a genotype heterozygous for two or more wild type genes (for example, Aa/Bb) and an endosperm having a genotype heterozygous for such genes (for example, AAa/BBb or AAa/bbB or aaA/BBb or aaA/bbB) and the starch produced therefrom.

Abstract: The invention relates to pyridazinoquinoline compounds of the formulas B and B′ wherein Ring A is selected from an ortho fused aromatic or heteroaromatic five- or six-membered ring and R1, R3 and R4 are substituents selected from halo, OH, OCF3, NO2, CN, NR′R″, SO2NR′R″, SOmR′alkyl, and a variety of alkyl, aryl, heterocyclic and heteroaryl groups, to pharmaceutical compositions containing them and to methods utilizing them for the treatment of neurological disorders.

Abstract: The invention concerns pharmaceutically useful peptide derivatives of the formula (I), P—R1—R2—R3—R4, in which P, R1, R2, R3, and R4 have the various meanings defined herein, and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel peptide derivatives are of value in treating MHC class II dependent T-cell mediated autoimmune or inflammatory diseases, such as rheumatoid arthritis. The invention further concerns processes for the manufacture of the novel peptide derivatives and the use of the compounds in medical treatment.

Abstract: 3-Isochromanone is prepared by contacting an o-xylene-&agr;,&agr;′-dihalide with carbon monoxide in a two-phase liquid medium, in which one phase is aqueous and the other phase is water-immiscible, in the presence of a catalyst and a hindered amine base.

Abstract: A compound of formula (I): wherein R1 represents a group of formula (A) where each of W, X, Y and Z and Z represents either a group CR or the nitrogen atom, provided that not more than two of W, X, Y and Z represent the nitrogen atom and where each R present is independently selected from hydrogen and halogen atoms and cyano, amino, hydrazino, acylamino, hydroxy, alkyl, hydroxyalkyl, alkoxy, haloalkyl, haloalkoxy, alkenyl, alkenyloxy, alkoxyalkenyl, alkynyl, carboxylic acyl, alkoxycarbonyl, aryl and heterocyclyl groups, said groups comprising up to 6 carbon atoms, and wherein R2 represents hydrogen or cyano or a group selected from alkyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, aralkenyl, alkynyl, alkoxycarbonyl, alkanesulfonyl, arenesulfonyl, alkanyloxycarbonyl, aralkyloxycarbonyl, aryloxycarbonyl, heterocyclylalkyl, carbamyl or dithiocarboxyl groups, said groups comprising from 1 to 15 carbon atoms, said groups being optionally substituted with one or more substituents selecte

Abstract: Expression of genes inserted into plants by transformation is controlled by the use of a promoter selected from Aco1, Aco2 and Aco3, the sequences of which are given. The level of expression obtained by use of these promoters varies with the stage of development of the plant.

Abstract: An agrochemical composition packaged in a water soluble or water dispersible sachet is taught. The agrochemical composition is comprised of water-soluble, agrochemically active agent, water and an agent to minimize water loss through the walls of the sachet, wherein the is an ester of an alkyl, alkenyl, aryl, or arylalkyl acid; an ester or a naturally occurring oil; or a mineral or a synthetic oil; provided that the agent is not dibutylphtalate.

Abstract: The present invention provides a phenanthroline derivative of formula (I) wherein, for example, R1 is hydrogen, carboxy, cyano, nitro, (1-4C)alkyl, (1-6C)alkoxycarbonyl, (1-4C)alkylamino, (2-4C)alkanoyl, (1-4C)alkoxy-(2-4C)alkoxy-(2-4C)alkoxycarbonyl or N-[amino-(2-8C)alkyl]carbamoyl; R2 is, for example, hydrogen, carboxy, (1-6C)alkoxycarbonyl, carbamoyl, N-(1-8C)alkylcarbamoyl, N,N-di-(1-8C)alkylcarbamoyl, N-(1-4C)alkylcyclohexylcarbamoyl, 1,2,3,4-tetrahydro-isoquinolin-2-ylcarbonyl or N,N-[di-(1-4C)alkyl]thiocarbamoyl; R3 and R4, which may be the same or different, are, for example, hydrogen or halo; and R5 is, for example, hydrogen, di-(1-4C)alkylamino or halo; or a pharmaceutically-acceptable salt thereof. The invention further provides pharmaceutical compositions comprising phenanthroline derivatives, processes for making the same and their use in producing an anti-fibroproliferative effect.

Abstract: An ink comprising water, a water-dissipatable polymer and a dye of the Formula (1): wherein: R1 is optionally substituted alkyl or optionally substituted aryl; R2 is H, optionally substituted alkyl or optionally substituted aryl; R5 is H or optionally substituted alkyl; and R3 and R4 are each independently optionally substituted alkyl or optionally substituted aryl, or R3 and R4 together with the CH group to which they are attached from an optionally substituted 5- or 6- membered ring. Also claimed are dyes and ink jet printing processes.